CTD & eCTD Dossier Preparation Services at the Celesta Healthcare clinical research centre
Regulatory Affairs · CTD & eCTD Dossiers

CTD & eCTD Dossier Preparation Services

A dossier is the single document your product is judged by. We compile Modules 1–5 from primary sources — manufacturing data we understand and clinical reports we generate — then publish and validate the eCTD so the science reaches a reviewer, not a rejection queue.

M1–M5
Full Module
Compilation
3
Formats — CTD,
eCTD & ACTD
65+
Studies Feeding
Module 5
Global
US · EU · India
· Brazil · ASEAN
Get a Proposal
All Regulatory Affairs
Overview

What Is Pharmaceutical Dossier Preparation?

Dossier preparation is the discipline of assembling everything a regulator needs to approve your product — administrative documents, quality (CMC) data, nonclinical evidence, and clinical study reports — into the exact structure the target agency requires. For most of the world that structure is the ICH Common Technical Document: five modules, each with defined contents, granularity, and cross-references. Submitted electronically with an XML backbone, the same dossier becomes an eCTD; reshaped into four parts for South-East Asia, it becomes an ACTD.

Most submissions do not fail on science. They fail on assembly — a missing stability commitment, a specification that contradicts the batch data two modules away, a PDF that breaks the agency’s technical validation. Every one of those errors costs a review cycle, and review cycles are measured in months. That is why serious dossier work starts with a gap analysis: a systematic comparison of the data you hold against what the agency will demand, done before a single module is written.

Celesta Healthcare prepares dossiers from an unusual position. We work with WHO-GMP manufacturing every day, so Module 3 is built by people who read batch records and stability protocols natively — and our own clinical research division generates the BA/BE study reports that anchor Module 5 at a DCGI-mandated, ANVISA-approved facility in Pune. One core dossier, compiled from primary sources, then adapted market by market.

CTD — Common Technical Document

The ICH-standard dossier format accepted by regulators worldwide. Five modules carry the administrative, summary, quality, nonclinical, and clinical evidence for a product in a fixed, reviewer-friendly structure.

eCTD Publishing

The conversion of a CTD dossier into a validated electronic submission — an XML backbone, granular PDFs, bookmarks and hyperlinks, and lifecycle sequences — that must pass the agency’s technical validation before any reviewer sees it.

Module Map

CTD Modules 1–5 — Contents and Ownership

Five modules, five different skill sets. This is what goes into each — and who on our team prepares it.

CTD dossier modules mapped to their contents and the team that prepares each
ModuleWhat It ContainsWho Prepares It
Module 1 — AdministrativeRegion-specific forms, cover letters, application fees, proposed labeling and product informationRegulatory affairs team, rebuilt per target market
Module 2 — SummariesQuality Overall Summary, nonclinical and clinical overviews and written summariesRegulatory medical writers working from Modules 3–5
Module 3 — Quality (CMC)Drug substance and drug product data: manufacturing process, controls, specifications, stabilityCMC specialists with hands-on WHO-GMP manufacturing exposure
Module 4 — NonclinicalPharmacology, pharmacokinetics, and toxicology study reportsNonclinical writers; literature-based for most generics
Module 5 — ClinicalClinical study reports including BA/BE studies, biopharmaceutic and PK dataOur clinical division — studies run and reported in-house
Services

Dossier Services End to End

From the first gap report to the final validated sequence — one team owns the dossier.

Regulatory Gap Analysis

Your existing data mapped against target-agency requirements — missing studies, documents, and inconsistencies flagged before compilation begins.

Module 1–5 Compilation

Full CTD authoring and assembly, with Module 2 summaries written from the source data rather than pasted from it.

eCTD Publishing & Validation

XML backbone, granular PDFs, bookmarks, hyperlinks, and lifecycle sequences — validated against agency criteria before filing.

ACTD & ROW Adaptation

The core dossier reshaped into ASEAN CTD or country-specific formats for emerging markets, without rewriting the evidence.

Query & Deficiency Responses

Structured, deadline-tracked responses to agency questions, written by the same team that built the dossier.

Lifecycle Sequences

Variations, renewals, and labeling updates published as clean eCTD sequences that keep the dossier history coherent.

The Celesta Difference

Modules 3 and 5 From Primary Sources

Most dossier consultants compile documents that other people generated. We work with WHO-GMP manufacturing daily, so batch records, process validation, and stability data read as familiar ground — and Module 5 is anchored by BA/BE reports from our own DCGI-mandated, ANVISA-approved clinical facility, where 75+ LC-MS/MS methods stand validated and 65+ studies have been executed. When a reviewer questions the dossier, the people who answer are the people who built the evidence.

M1–M5
Full Dossier Coverage
3
Formats Prepared
65+
Studies Executed
75+
Validated Methods
How It Runs

From Gap Report to Validated Submission

  1. 01

    Scoping & Market Map

    Product, target markets, and pathways agreed — which format each agency needs and what one core dossier can serve.

  2. 02

    Gap Analysis

    A written gap report: every missing document, study, and inconsistency, with a remediation plan and realistic timeline.

  3. 03

    Source Document Collection

    Batch records, stability data, method validations, and study reports gathered and quality-checked against specifications.

  4. 04

    Module Authoring & Review

    Modules 3–5 compiled, Module 2 summaries written, Module 1 built per region — with cross-module consistency checks throughout.

  5. 05

    eCTD Publishing & Validation

    The dossier published to eCTD (or adapted to ACTD), run through technical validation, and every error resolved before filing.

  6. 06

    Submission & Query Support

    Filing, tracking, and structured responses to agency questions until approval — then lifecycle sequences after it.

Why Celesta

Why Sponsors Choose Us for Dossier Preparation

  • Manufacturing-side CMC fluency for Module 3 that pure consultants lack
  • Module 5 anchored by BA/BE studies from our own DCGI-mandated, ANVISA-approved facility
  • CTD, eCTD, and ACTD prepared and adapted by one accountable team
  • Technical validation before filing — no format rejections at the gateway
  • One core dossier strategy serving multiple markets efficiently
  • Structured query and deficiency response management to approval
FAQs

Dossier Preparation — Frequently Asked Questions

1. What is dossier preparation in the pharmaceutical industry?
Dossier preparation is the compilation of all evidence about a pharmaceutical product — administrative information, quality (CMC) data, nonclinical studies, and clinical study reports — into the structured format a regulatory agency requires for marketing approval. For most markets that format is the ICH Common Technical Document (CTD), organized into five modules and submitted either as documents or electronically as an eCTD.
2. What is the difference between CTD and eCTD?
The content is identical — the five modules defined by ICH M4. The difference is the container. A CTD is a document-based dossier; an eCTD packages the same documents with an XML backbone that tells the agency’s review system where every file belongs and how each new sequence updates the last. The US FDA and EMA mandate eCTD for most application types, and an eCTD must pass technical validation before the agency accepts it for review.
3. What is gap analysis in regulatory affairs?
A gap analysis is a systematic comparison of the data and documents you hold against what the target agency requires for your product and pathway. The output is a gap report: missing studies, absent documents, and inconsistencies between sections, each with a remediation action. Done before compilation starts, it converts an open-ended dossier project into a defined scope with a defensible timeline.
4. Is eCTD mandatory for US FDA and EMA submissions?
Yes, for most application types. The US FDA requires eCTD format for NDAs, ANDAs, BLAs, and master files, and the EMA requires eCTD across the centralised procedure — legacy paper and NeeS formats are no longer accepted in these markets. Several other agencies, including Health Canada, have followed. India and many emerging markets still accept document-based CTD dossiers.
5. What does eCTD validation involve?
Before filing, the eCTD package is checked against the agency’s published technical validation criteria: file formats and PDF properties, folder structure, XML backbone integrity, lifecycle attributes, bookmarks, and hyperlinks. Findings are classed by severity, and high-severity errors cause the submission to be rejected before any reviewer sees the science. We validate every sequence and clear all errors before it leaves our hands.
6. How long does CTD dossier preparation take?
For a generic product with complete source data, compilation and publishing typically run 8–12 weeks. The honest driver is source-document readiness: missing stability data or an unvalidated method extends the timeline far more than the writing does. That is exactly what the up-front gap analysis quantifies — you get a real date, not an optimistic one.
7. Which countries use the ACTD format?
The ASEAN Common Technical Dossier is used by ASEAN member states — Thailand, Malaysia, Indonesia, the Philippines, Vietnam, Singapore, Myanmar, Cambodia, Laos, and Brunei. It reorganizes the dossier into four parts instead of five modules. We adapt an existing CTD into ACTD rather than writing from scratch, which preserves consistency and saves weeks.
8. Can the same dossier be used for multiple countries?
Largely yes — that is the point of the CTD. Modules 2–5 form a core dossier reused across markets, while Module 1 is rebuilt for each region. Real adaptation work remains: format conversion to eCTD or ACTD, market-specific stability zone requirements, and local labeling. We plan the core dossier around the full market list from day one so later filings are adaptations, not rebuilds.

More Regulatory Affairs Services

Every study type under one roof — explore the rest of our regulatory affairs capabilities.

Regulatory Affairs Overview

DCGI & CDSCO Approvals

Clinical trial applications, BE-NOCs, test licences, and new drug approvals under the NDCT Rules, 2019.

Learn More

ANDA Dossiers

US FDA generic submissions with Module 3 CMC built by people who work with manufacturing daily.

Learn More

ANVISA / Brazil

BE studies at our ANVISA-approved centre plus CTD dossiers and query management for Brazil.

Learn More

Discuss Your Dossier Preparation Requirement

Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.

Get a ProposalContact Us

Need something? Chat with us!